Mode
Text Size
Log in / Sign up

Serum procalcitonin shows moderate accuracy for sepsis diagnosis in critically ill ICU patients

Serum procalcitonin shows moderate accuracy for sepsis diagnosis in critically ill ICU patients
Photo by insung yoon / Unsplash
Key Takeaway
Interpret serum procalcitonin results cautiously for sepsis diagnosis in critically ill ICU patients due to moderate accuracy.

This systematic review and diagnostic meta-analysis evaluated the accuracy of serum procalcitonin (PCT) for diagnosing sepsis in 1,098 critically ill adult patients with suspected infection admitted to intensive care units. The comparator was diagnosis based on Sepsis-3 criteria, with 635 patients diagnosed with sepsis and 89 with septic shock. The analysis did not report specific follow-up duration or safety data related to PCT measurement.

The meta-analysis found PCT had a pooled sensitivity of 0.72 (95% CI, 0.68-0.75) and specificity of 0.65 (95% CI, 0.61-0.69) for diagnosing sepsis. The pooled positive likelihood ratio was 2.45 (95% CI, 1.62-3.68), negative likelihood ratio was 0.38 (95% CI, 0.28-0.53), and diagnostic odds ratio was 7.08 (95% CI, 3.69-13.58). The area under the summary receiver operating characteristic curve was 0.79 (95% CI, 0.73-0.86).

Safety and tolerability data for PCT measurement were not reported in the analysis. The authors noted low certainty for both sensitivity and specificity estimates, though specific study limitations were not detailed. Funding sources and potential conflicts of interest were also not reported.

For clinical practice, these findings suggest PCT has moderate diagnostic accuracy for sepsis in critically ill ICU patients but should not be used in isolation. The evidence has low certainty, and clinicians should integrate PCT results with comprehensive clinical assessment rather than relying on them as definitive diagnostic tools.

Study Details

Study typeMeta analysis
Sample sizen = 1,098
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
INTRODUCTION: Procalcitonin (PCT) has been a blue-eyed-boy in diagnosing sepsis in previous years. The aim of this systematic review and meta-analysis was to assess the accuracy of PCT for the diagnosis of sepsis, according to the recent Sepsis-3 criteria, in adult patients admitted to the intensive care unit (ICU). METHODS: We searched several electronic databases, including PubMed, Science Direct, Wiley, Cochrane, and Google Scholar from the inception of the Sepsis-3 diagnostic criteria (January 1, 2016) until May 31, 2025, for randomized controlled trials, cohort, and case-control studies that assessed the diagnostic accuracy of PCT for sepsis using the Sepsis-3 criteria among critically ill adult patients with suspected infection. We performed a random effect diagnostic meta-analysis, evaluated the risk of bias of individual studies using the QUADAS tool, and assessed certainty of evidence using GRADE methodology. RESULTS: We included 10 studies comprising 1098 patients. Of these, 635 patients were diagnosed with sepsis based on Sepsis-3 criteria, including 89 patients with septic shock. The pooled sensitivity of PCT for diagnosing sepsis was 0.72 (95 % CI [confidence interval], 0.68-0.75, low certainty) and the pooled specificity was 0.65 (95 % CI, 0.61-0.69, low certainty). The pooled positive likelihood ratio was 2.45 (95 % CI [confidence interval], 1.62-3.68), The negative likelihood ratio was 0.38 (95 % CI, 0.28-0.53), and the pooled diagnostic odds ratio was 7.08 (95 % CI, 3.69-13.58). The area under the summary receiver operating characteristic curve of PCT was 0.79 (95 % CI 0.73-0.86). CONCLUSION: Based on pooled analysis, PCT has a moderate sensitivity and specificity for diagnosis of sepsis in ICU patients with suspected infection. These results suggest clinicians should be cautious about using PCT to facilitate the diagnosis of sepsis in critically ill adults with suspected infection. Given the ongoing uncertainty, further high-quality data in this population is needed.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.